Time is also important for putting the number needed to treat (NNT) into perspective. For example, REDUCE-IT trial showed that Vascepa elicited a 26% RRR in 3-point MACE (Absolute Risk Reduction, ARR, 3.6%) at a median dosing period of 4.9 years (58 months). So 28 people would need to be treated for close to 5 years with Vascepa to prevent one 3-point MACE event.

Right now, BETonMACE likely has a median dosing period of close to 2 years and should end up with a final median dosing period below 2.5 years once trial is complete. So just hypothetically if apabetalone also elicits a 26% RRR in 3-point MACE, the NNT will be calculated from BETonMACE's median dosing period of 2 to 2.5 years; much earlier than REDUCE-IT. Let's also assume that the ARR in BETonMACE is 3.6% and the NNT is 28. Those 28 patients would only need to be treated for 2 to 2.5 years with apabetalone to prevent one 3-point MACE event.

BearDownAZ